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This study was undertaken to characterize the pharmacokinetics and bioavailability of voriconazole in adult
lung transplant patients during the early postoperative period, identify factors significantly associated with
various pharmacokinetic parameters, and make recommendations for adequate dosing regimens. Thirteen
lung transplant patients received two intravenous infusions (6 mg/kg, twice daily [b.i.d.]) immediately post-
transplant followed by oral doses (200 mg, b.i.d.) for prophylaxis. Blood samples (9/interval) were collected
during one intravenous and one oral dosing interval from each patient. Voriconazole plasma concentrations
were measured by high-pressure liquid chromatography (HPLC). NONMEM was used to develop pharmaco-
kinetic models, evaluate covariate relationships, and perform Monte Carlo simulations. There was a good
correlation (R2  0.98) between the area under the concentration-time curve specific for the dose evaluated
(AUC0–) and trough concentrations. A two-compartment model adequately described the data. Population
estimates of bioavailability, clearance, Vc, and Vp were 45.9%, 3.45 liters/h, 54.7 liters, and 143 liters. Patients
with cystic fibrosis (CF) exhibited a significantly lower bioavailability (23.7%, n  3) than non-CF patients
(63.3%, n  10). Bioavailability increased with postoperative time and reached steady levels in about 1 week.
Vp increased with body weight. Bioavailability of voriconazole is substantially lower in lung transplant patients
than non-transplant subjects but significantly increases with postoperative time. CF patients exhibit signifi-
cantly lower bioavailability and exposure of voriconazole and therefore need higher doses. Intravenous ad-
ministration of voriconazole during the first postoperative day followed by oral doses of 200 mg or 400 mg
appeared to be the optimal dosing regimen. However, voriconazole levels should be monitored, and the dose
should be individualized based on trough concentrations as a good measure of drug exposure.
Invasive aspergillosis is one of the most severe complications
after transplantation (22), with a mortality rate as high as 88.1%
(19). Voriconazole (V-Fend), a triazole antifungal agent, has be-
come the treatment of choice for invasive aspergillosis (14, 31).
The standard use of a prophylactic voriconazole regimen imme-
diately after transplant in lung transplant patients at our institu-
tion offered the opportunity to assess voriconazole pharmacoki-
netics in this unique patient population.
There is large inter- and intraindividual variability in plasma
concentrations of voriconazole regardless of the route of ad-
ministration or the type of patient population (29). Low vori-
conazole exposure is associated with poor outcomes in patients
with aspergillosis (7, 11, 23, 25–27), while high voriconazole
exposure is associated with an increased risk for toxicity, in-
cluding visual disturbances, elevated transaminase levels, cen-
tral nervous system disorders (e.g., encephalopathy), and elec-
trolyte disturbances (4, 7, 26, 28). Therefore, it is important to
optimize the use and exposure of voriconazole.
The bioavailability of voriconazole after oral administration
is 96% in non-transplant populations (24). However, gastroin-
testinal complications observed after transplant surgery (3, 5,
18, 33) may cause clinically significant lower bioavailability of
voriconazole. Therefore, it is important to understand bioavail-
ability of voriconazole in transplant patients.
To date, the bioavailability of voriconazole in transplant
patients and the pharmacokinetics of voriconazole in lung
transplant patients have not been reported. There is limited
information on pharmacokinetics of voriconazole in other
transplant populations (13, 15). Population approaches were
used previously to investigate the pharmacokinetics of voricon-
azole in a limited number of studies (13, 17, 20, 21, 32).
The objectives of this prospective single-center observational
study of voriconazole were to characterize the pharmacokinetics
and bioavailability of voriconazole in lung transplant patients in
early postoperative period, to determine the extent of interindi-
vidual variability in pharmacokinetics of voriconazole, to identify
factors significantly associated with pharmacokinetic parameters,
and to make recommendations for adequate dosing regimens.
MATERIALS AND METHODS
Patients. The protocol was approved by the institutional review board at the
University of Pittsburgh. Lung transplant recipients who were started on a
voriconazole prophylactic regimen immediately after transplant as part of their
standard clinical care and who gave informed consent were enrolled in this
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prospective study regardless of the reason for transplant. Two intravenous doses
were administered first as a 2-hour intravenous infusion (6 mg/kg, twice daily
[b.i.d.]) followed by oral doses (200 mg, b.i.d.) for a duration of 3 months
posttransplant. The exclusion criteria were as follows: age under 18, coadminis-
tration of medications known to influence voriconazole pharmacokinetics, ad-
ministration of voriconazole to treat an active fungal infection, pretransplant
voriconazole administration, and voriconazole dosing regimens other than that
associated with fixed oral dosage. Complete dosing history, demographic data,
laboratory tests, and current medication use were recorded. All patients received
tacrolimus as their primary immunosuppressive agent.
Blood sampling and analytical assay. Serial blood samples (7 ml) were col-
lected within one intravenous and one oral dosing interval from each patient.
The sampling time was just prior to (0 h) and at 0.5, 1, 1.5, 2, 4, 6, 8, and 12 h
following the second intravenous dose and following administration of a mini-
mum of 5 oral doses (range from the 5th to 37th dose; mean, 15th dose). Blood
samples were processed and analyzed for voriconazole plasma concentration
using a validated high-pressure liquid chromatography (HPLC) method de-
scribed previously (15). The assay precision (intraday and interday variability)
was 1.3% to 9.0% (0.2 to 9 g/ml), and the assay bias (deviation from actual
value) was 0.7% to 3.1% (0.5 to 9 g/ml). The linearity range was 0.2 to 9 g/ml
(R2  0.9998).
Noncompartmental pharmacokinetic analysis. The difference between trough
concentrations prior to oral dosing (C0) and at 12 h after oral dosing (C12) was
tested using a paired two-tailed Student t test to confirm attainment of steady
state. Area under the plasma concentration-versus-time curve specific for the
dose evaluated (AUC0–) was calculated using the trapezoid rule and reverse
superposition principle. Time to peak concentration (Tmax) and peak plasma con-
centrations (Cmax) were directly read off the concentration-versus-time profiles.
Population pharmacokinetic analysis. A nonlinear mixed-effects pharmacoki-
netic model (base model) was developed using NONMEM 6.2.0 (GloboMax,
Hanover, MD) using the first-order conditional estimation method with interac-
tion. Correlations between pharmacokinetic parameters were always incorpo-
rated and estimated. One- and two-compartment models were tested with first-
and zero-order elimination and a Michaelis-Menten elimination process, since
nonlinear pharmacokinetics of voriconazole has been reported (24). Interindi-
vidual variability was described using exponential model Pij  TV(Pj)  eij,
where Pij is the ith individual’s estimate of the jth pharmacokinetic parameter,
TV(Pj) is the typical value of the jth pharmacokinetic parameter, and ij is a
random variable for the ith individual and the jth pharmacokinetic parameter
distributed with a mean of zero and a variance of j2. Residual variability was
described using combined error model Cobs  Cpred  (1  ε)  ε, where Cobs
and Cpred are the observed and predicted concentrations, respectively, and ε and
ε are normal random variables with means of zero and variances of 	2 and 	2,
respectively. The adequacy of fitting was examined by plotting predicted versus
observed concentrations (goodness of fit), concentrations versus time profiles
and weighted residuals versus predicted concentrations.
Covariate relationship exploration. Association between patient variables and
pharmacokinetic parameters were first visually evaluated by plotting empirical
Bayes estimates (EBE) against patient variables. Patient variables were then
incorporated into the base model one at a time using at least 13 approaches to
associate the patient variable with the parameter. A patient variable was con-
sidered significant if all the following criteria were met: (i) a decrease in objective
function value (OFV) of 6.63 for 1 degree of freedom (P 
 0.01), (ii) no
significant trend in EBE-versus-patient variables plots, (iii) improved goodness
of fit, (iv) reduced interindividual variability, and (v) clinical plausibility for
incorporating the patient variable.
Precision of parameter estimation, stability of the covariate models, and nor-
mality of the distribution of the parameter estimates were evaluated using boot-
strapping (resampling repeated 3,500 times) using Wings for NONMEM (http:
//wfn.sourceforge.net). Nonparametric statistics (median and 95% confidence
interval) of parameter estimates were obtained from bootstrapping.
Monte Carlo simulations. Voriconazole concentration-versus-time profiles in
patients with and without cystic fibrosis (CF) (200 mg, oral, b.i.d.) were simulated
using NONMEM to demonstrate that CF patients may exhibit significantly lower
exposure of voriconazole than non-CF patients and that CF patients may expe-
rience underexposure of voriconazole, with trough concentrations of 
1 g/ml.
The simulation procedure is based on drawing random samples for each of the
pharmacokinetic parameters from their statistical distributions, reflecting inter-
individual variability. Every random draw generates a parameter set that char-
acterizes the pharmacokinetics of a “virtual” subject and is subsequently used to
generate the concentration-versus-time profile of this virtual subject. A total of
1,500 virtual CF subjects and 1,500 virtual non-CF subjects were simulated using
this procedure. This simulation ensemble closely matches the original population
statistics. Concentration-versus-time profiles of the virtual populations were
summarized and compared by their median and 5% and 95% percentiles (90%
prediction interval). The width of the 90% prediction interval reflects the degree
of interindividual variability in the original population.
In order to illustrate voriconazole exposure in different clinical scenarios
and thus make clinical recommendations for adequate dosing regimens, vori-
conazole concentration-versus-time profiles were simulated for five hypothet-
ical dosing regimens (b.i.d.): oral administration only (200, 400, and 600 mg)
or combined administration of two doses of a 2-hour intravenous infusion (6
mg/kg) followed by oral administration (200 mg and 400 mg). A total of 1,500
virtual subjects were simulated for each regimen using the same procedure
mentioned above. In addition, simulation of individual profiles was also
performed using a fixed dose of 200 mg or a body weight-adjusted dose of 3
mg/kg and compared with each other, in order to evaluate whether the variability
among the pharmacokinetic profiles was reduced by using a body weight-adjusted
dose compared to a fixed dose.
RESULTS
Patients. A total of 13 patients were enrolled in this study.
Table 1 summarizes the characteristics of the patients, includ-
ing the primary diagnosis, age, body weight, race, gender, days
posttransplant on the day of the oral study, and laboratory
biochemical profiles prior to transplant, immediately after
transplant, and on the day of the oral study. One patient did
not complete the oral study.
There was a wide variation in voriconazole plasma concen-
trations (Fig. 1). Most voriconazole plasma concentrations
(72.5%) were maintained within 1 to 6 g/ml, while 17.9% and
9.7% of voriconazole plasma concentrations were below 1
g/ml or above 6 g/ml, respectively.
Noncompartmental analysis. Trough concentrations (C0
and C12) were not significantly different (P  0.82), and the
difference between the trough concentrations (C12  C0)/C12
averaged2.7%, indicating that steady state had been reached
in most of the patients at the time of the oral study. Figure 2
illustrates a good correlation between voriconazole trough
plasma concentrations and the corresponding AUC0– for
both intravenous infusion (non-steady state, R2  0.86) and
oral dose (steady state, R2  0.98). Tmax (mean  standard
deviation [SD]) for oral dose was 1.9  1.3 h. Cmax (mean 
SD) for intravenous infusion and oral dose was 5.9 2.2 g/ml
and 3.6  2.6 g/ml, respectively.
Population pharmacokinetic analysis. A two-compartment
model with first-order absorption and elimination adequately
described the data. The population estimates (interindividual)
of bioavailability, clearance, volume of distribution of the cen-
tral compartment (Vc) and peripheral compartment (Vp), in-
tercompartment clearance (Q), and absorption rate constant
(ka) were 45.9% (82.9%), 3.45 liters/h (107%), 54.7 liters
(78.4%), 143 liters (88.3%), 22.6 liters/h (50.1%) and 0.591 h1
(115.2%). The proportional and additive residual variability
was 0.31 and 0.49 g/ml, respectively. Individual predictions
agreed well with observations (Fig. 3). Weighted residuals were
approximately normally distributed and were mostly within
about 2 units of the null ordinate.
Based on the individual estimates obtained from the base
model, mean bioavailability (SD) was 23.7% (19.4%, n  3)
and 63.3% (15.2%, n  10) in CF and non-CF patients, re-
spectively. Bioavailability was significantly lower in CF patients
than non-CF patients (P  0.0032, two-tailed Student’s t test).
Covariate relationship exploration. Among all the 12 pa-
tient variables tested (the primary diagnosis, age, body weight,
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race, gender, postoperative time on the day of the oral study,
alkaline phosphatase, alanine aminotransferase, aspartate ami-
notransferase, gamma-glutamyl transpeptidase, serum creati-
nine, and creatinine clearance), three were found to be signif-
icantly associated with pharmacokinetic parameters in lung
transplant patients in this study: cystic fibrosis, postoperative
time, and body weight.
Model 1: cystic fibrosis (CF). The most important patient
variable associated with bioavailability was CF. OFV decreased
by 11.65 from 47.55 (base model) to 59.20 when CF was
incorporated in bioavailability, indicating substantial model
improvement (P  0.0006). Interindividual variability in bio-
availability decreased by 30.7% from 82.9% (base model) to
57.5%, while interindividual variability in other pharmacoki-
netic parameters did not change significantly.
The association between CF and bioavailability (F) was best
described using the equation F  FCF  F  NCF (model 1),
where FCF denotes bioavailability of CF patients, F denotes
the difference in bioavailability between CF and non-CF pa-
tients, and NCF is 1 for non-CF patients and 0 for CF patients.
Population estimates of FCF and F (95% confidence interval)
were 10.7% (1.1%  23.4%) and 72% (35.3%  97.2%),
respectively. Based on the model, bioavailability of voricon-
azole was significantly lower in CF patients (10.7%) than
non-CF patients (82.7%), by 87%.
Model 2: postoperative time (POT). Another important fac-
tor associated with bioavailability was POT. OFV decreased by
10.94 from 47.55 (base model) to 58.49 when POT was
incorporated in bioavailability, indicating substantial model
improvement (P  0.0009). The association between POT and
bioavailability (F) was best described using the equation F 
(Fmax  POT)/(POT  Fc) (model 2), where Fmax denotes the
maximal bioavailability that can be reached in the patients in
this study, and Fc is a constant. Interindividual variability was
incorporated both in Fmax and Fc and estimated. Population
estimates (95% confidence interval) of Fmax and Fc were 61.9%
(43.5%  72.8%) and 1.97 h (0.04  4.2), respectively. The
interindividual variability of Fmax and Fc was 61.5% and
217.3%, respectively. Even the maximal bioavailability (61.9%)
in lung transplant patient population was still much lower than
that in non-transplant subjects (96%). The low value of Fc
indicates that bioavailability would increase rapidly with POT.
According to the equation and individual parameter esti-
mates obtained from model 2, bioavailability of voriconazole
significantly and rapidly increased with POT in most of the
patients and eventually reached maximal levels within 1 week
posttransplant (Fig. 4). Figure 4 also shows that bioavailability
was significantly lower in CF patients than non-CF patients.
The large variability demonstrated in Fig. 4 is consistent with
the large interindividual variability in Fmax and Fc.
Model 3: body weight (WT). Vp significantly increased with
WT. OFV decreased by 7.29 from 47.55 (base model) to
54.84 when WT was incorporated in Vp, indicating substan-
tial model improvement (P  0.0069). Interindividual variabil-
ity in bioavailability decreased by 31.9% from 88.3% (base
model) to 61.2%, while interindividual variability in other
pharmacokinetic parameters did not change significantly. The
association between Vp and WT was best described using the
equation Vp  TV(Vp)  (WT/
—
W
–
T)a (model 3), where TV(Vp)
denotes the typical value of Vp in the patients in this study, i.e.,
the Vp in a patient with average body weight (68 kg), and a is
a constant to be estimated. Population estimates of TV(Vp)
and a were 148 liters (95% confidence interval, 84 223 liters)
and 3.56 (95% confidence interval, 0.43  6.33), respectively.
Monte Carlo simulations. The statistical distribution of
pharmacokinetic parameters and interindividual variability ob-
tained from model 1 (see above) was used to simulate CF and
non-CF virtual subjects (Fig. 5a). Median voriconazole plasma
concentration and median AUC were 6.7 times higher in
non-CF patients than CF patients. Furthermore, the 90% pre-
diction interval for CF patients did not include the median
concentration-versus-time profiles of non-CF patients, and
vice versa. This indicates significantly lower exposure of vori-
conazole in CF patients than non-CF patients.
TABLE 1. Characteristics of patients
Parameter Resulta
No. of patients with: ................................................................................................................................
Cystic fibrosis ........................................................................................................................................ 3
Emphysema ........................................................................................................................................... 5
Idiopathic pulmonary fibrosis ............................................................................................................. 4
Scleroderma .......................................................................................................................................... 1
Patient age (yr) .........................................................................................................................................50.9  16.1 (19–70)
Wt (kg) ......................................................................................................................................................68.0  15.2 (46–91)
Ideal body wt (kg) ....................................................................................................................................59.6  8.2 (45.5–75.3)
Race (Caucasian/other) ........................................................................................................................... 12/0
Gender (male/female).............................................................................................................................. 7/6
Days posttransplant on day of oral study.............................................................................................. 8.5  4.4 (3–19)
Alkaline phosphatase (U/liter)b..............................................................................................................82.4  31.8 (54–169)
Alanine aminotransferase (U/liter)b ......................................................................................................30.3  8.3 (22–52)
Aaspartate aminotransferase (U/liter)b .................................................................................................28.1  14.5 (20–75)
Gamma-glutamyl transpeptidase (U/liter)b ...........................................................................................35.1  19.0 (15–71)
Serum creatinine (mg/dl)c .......................................................................................................................0.78  0.16 (0.5–1)/0.85  0.22 (0.5–1.1)
Creatinine clearance (ml/min)c...............................................................................................................85.6  36.9 (55.6–177.8)/85.7  40.4 (40.5–177.8)
a Values are means  standard deviations (range) unless otherwise specified.
b Value measured before the transplantation.
c Shown in the format measurement within 1 day after the transplantation/measurements on the day of the oral study.
4426 HAN ET AL. ANTIMICROB. AGENTS CHEMOTHER.
 o
n
 N
ovem
ber 4, 2015 by University of Queensland Library
http://aac.asm
.org/
D
ow
nloaded from
 
The 90% prediction interval of the entire concentration-
versus-time profiles (including peak levels) in CF patients re-
mained below 1 g/ml for the first 3 days posttransplant. The
90% prediction interval of trough concentration in CF patients
remained below 1 g/ml for the first 4 days posttransplant. Me-
dian concentration-versus-time profiles in CF patients remained
below 0.5 g/ml for the duration of the study. This indicates
underexposure of voriconazole in CF patients, with trough con-
centrations of 
1 g/ml in 90% of the patients during the first 4
days posttransplant. In addition, the large interindividual variabil-
ity is confirmed by wide 90% prediction intervals.
Statistical distributions of pharmacokinetic parameters and
interindividual variability obtained from model 2 (see above)
were used to simulate different dosing regimens. Median
trough concentrations stayed above 1 g/ml after the first load-
ing dose and were maintained between 2 and 3 g/ml at steady
state when patients received two 2-hour intravenous infusions
followed by oral doses (Fig. 5b). In contrast, simulation with
mere oral administration (b.i.d.) at 200 mg, 400 mg, and 600
mg resulted in median trough concentrations below 1 g/ml for
the first 3.5 days, 1.5 days, and 1 day posttransplant, respec-
tively. In addition, simulated individual profiles using a fixed
dose of 200 mg or a body weight-adjusted dose of 3 mg/kg were
compared with each other, and the variability among the phar-
macokinetic profiles was not reduced by using a body weight-
adjusted dose compared to a fixed dose, which confirmed the
adequacy of fixed oral dosing regimens.
DISCUSSION
This is the first evaluation of bioavailability of voriconazole
in transplant patients and the first pharmacokinetic study of
voriconazole in lung transplant patients.
Prospective intense sampling (nine samples per dosing in-
FIG. 1. Plasma concentration-versus-time profiles of voriconazole. (a) Individual plasma concentration-versus-time profiles of voriconazole
collected during an intravenous infusion dosing interval. (b) Mean plasma concentration-versus-time profiles of voriconazole with standard
deviations (error bars) collected during an intravenous infusion dosing interval. (c) Individual plasma concentration-versus-time profiles of
voriconazole collected during an oral dosing interval (one patient did not complete oral study). (d) Mean plasma concentration-versus-time profiles
of voriconazole with standard deviations (error bars) collected during an oral dosing interval.
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terval) in the early posttransplant period in a small group of
relatively homogenous patients (n  13) was used in this study
to provide accurate and precise parameter estimation. Oral
pharmacokinetic profiles of voriconazole are characterized by
an early and sharp increase of voriconazole concentration, with
the peak concentration being reached around 2 h after dosing.
This observation is consistent with rapid absorption of vori-
conazole and is similar to what has been observed in non-
transplant patients (24). Despite the relative homogeneity of
the population studied, a large interindividual variability in
voriconazole pharmacokinetics was demonstrated. This is con-
sistent with what was previously reported (15, 29). Nonlinear
pharmacokinetics was not observed in this study (a Michaelis-
Menten elimination process did not improve the fit).
The large interindividual variability in voriconazole expo-
sure has given rise to concerns about voriconazole dose man-
agement in transplant patients, especially when it results in
underexposure. Unpublished results (3,500 samples) from
our research group showed that nearly 15.2% of transplant
patients on recommended doses have undetectable trough
concentrations, and nearly 45% of the patients have trough
concentrations of 
1 g/ml. Drug underexposure may be
caused by decreased absorption or increased elimination.
Elimination of voriconazole is determined by liver function
and cytochrome P450 polymorphism. Therefore, elimination is
FIG. 4. Change of bioavailability of voriconazole over postopera-
tive time (POT) in patients with and without cystic fibrosis (CF).
Individual parameter estimates of bioavailability obtained from model
2 were plotted against postoperative time. Bioavailability significantly,
rapidly increased with POT in most of the patients, and eventually
reached the maximal level within 1 week after transplant. Bioavailability
was significantly lower in CF patients (dashed line) than non-CF patients
(solid line). Solid gray line, population estimates from model 2.
FIG. 2. Correlation between AUC0– and voriconazole trough plasma concentrations. (a) R
2  0.83 when AUC0– and trough concentrations
(C12) were correlated during an intravenous infusion dosing interval (non-steady state). (Inset) R
2  0.86 when a potential outlier is omitted. Two
patients had very similar C12 and AUC and therefore cannot be visually separated in the figure. (b) R
2  0.98 (dashed line) and R2  0.96 (solid
line) when AUC0– was correlated with trough concentrations (C0 [F] and C12 [], respectively) during an oral dosing interval (steady state; one
patient did not complete oral study).
FIG. 3. Goodness-of-fit of base model. Individual predictions
agreed well with observations (R2  0.96).
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unlikely to increase in transplant patients. Therefore, we hy-
pothesized that decreased bioavailability is responsible for un-
derexposure of voriconazole in transplant patients. In this
study, bioavailability of voriconazole was substantially lower
during the early postoperative period in lung transplant pa-
tients (45.9%) than in non-transplant subjects (96%), likely
due to gastrointestinal complications observed after transplant
surgery (3, 5, 18, 33).
Furthermore, we demonstrated that bioavailability of vori-
conazole was significantly lower in CF patients than non-CF
patients, by 87%. It is typical that the mean bioavailability
calculated using individual estimates of bioavailability ob-
tained from the base model (23.7% for CF patients and 63.3%
for non-CF patients) were different from the population esti-
mates in model 2 (10.7% for CF patients and 82.7% for
non-CF patients). Unlike the mean, the population estimate is
the posterior mode of the marginal likelihood distribution for
that parameter value versus the objective function (i.e., the
maximum likelihood point in the distribution). If the distribu-
tions are not strictly normal (log normal is enough to skew
this), the mean will not equal the mode.
The low voriconazole exposure observed in patients with CF
in this study agrees with the observations reported by Berge et
al. (2) that voriconazole plasma concentrations were 
0.5
g/ml in over 30% of CF lung transplant patients and 
1.5
g/ml in nearly 70% of the patients. However, those authors
did not perform a pharmacokinetic analysis to determine the
cause of underexposure, since only trough and peak concen-
trations from therapeutic drug monitoring were obtained. Pop-
ulation pharmacokinetic analysis and Monte Carlo simulation
in our study demonstrated that the reduced bioavailability in
CF patients is the potential cause of underexposure.
CF is well known to cause malabsorption and reduced bio-
availability of several highly lipophilic compounds, such as
vitamins A, D, E, and K (9), cyclosporine (30), and ibuprofen
(12). Due to its high lipophilicity and low water solubility,
absorption of voriconazole is associated with digestion of fat
and the subsequent formation of micelles. However, this pro-
cess is severely impaired in CF patients for many reasons,
including (i) pancreatic insufficiency, leading to decreased se-
cretion of pancreatic enzymes (lipase), (ii) reduced activity of
lipase due to low duodenal pH caused by decreased secretion
of pancreatic bicarbonate (16) and gastric acid hypersecretion
(6), (iii) precipitation of bile salts at low duodenal pH, leading
to low duodenal bile salt concentration and a diminished bile
salt pool (precipitated bile salts are not reabsorbed) (10), and
(iv) intestinal mucosal dysfunction, alterations in the intestinal
mucus layer, and accelerated intestinal transit time (8, 30).
It is important to identify factors that significantly contribute
to the large inter- and intraindividual variability of voricon-
azole in this population by exploring associations between pa-
tient variables and pharmacokinetic parameters. The 12 pa-
tient variables tested in this study covered a wide range of
values within each of the categories tested. Bioavailability in-
creased rapidly over POT and reached maximal levels within 1
week in most of the patients (Fig. 4), probably because of
improved gastrointestinal function over POT. The values of
CL/F and Vd/F of voriconazole have been reported to rapidly
and dramatically decrease with POT in liver transplant patients
(13). The authors of that study proposed increased bioavail-
ability with POT as the primary reason, which is partly sup-
ported by this study.
A final model was also built using a standard forward addi-
tion and reverse removal approach. However, despite the sta-
tistically significant improvement of the final model and the
covariate models (models 1, 2, and 3) compared to the base
model, visual inspection of the goodness-of-fit plots of the final
model and covariate models showed a corrected bias of pop-
ulation predictions only at low concentrations. This suggested
that the patient variables tested and selected in this study (CF,
POT, and body weight) explain only part of the variability in
the pharmacokinetics of voriconazole in lung transplant pa-
FIG. 5. Monte Carlo simulation. (a) Simulated voriconazole con-
centration-versus-time profiles during the first 2 days posttransplant in
lung transplant patients with and without cystic fibrosis (CF). The
median simulated voriconazole concentration in CF patients (solid
line) and non-CF patients (dashed line) with 90% prediction intervals
of CF patients (gray shading) and non-CF patients (hatching) is dis-
played. Extension of the profiles beyond 2 days posttransplant is not
shown. (b) Simulated voriconazole concentration-versus-time profiles
(extended until steady state was reached) in lung transplant patients
receiving two doses of 2-h intravenous infusion (6 mg/kg) followed by
oral doses (b.i.d.). The medians of simulated voriconazole concentra-
tion with intravenous infusion followed by oral dose of 200 mg (black
line) and 400 mg (gray line) are compared. Only the 90% prediction
interval for intravenous infusion followed by oral dose of 200 mg
(dashed line) is displayed.
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tients, while some other variables that were not collected in
this study are still needed to account for the remaining vari-
ability. Future studies should collect more variables and fur-
ther explore factors that are significantly associated with phar-
macokinetics of voriconazole in lung transplant patients.
The large variability in voriconazole exposure following
weight-adjusted or fixed doing regimens necessitates individu-
alizing voriconazole dosing to maximize therapeutic efficacy
and minimize toxicity in lung transplant patients. This is par-
ticularly important because simple efficacy measures for molds
to which patient dose can be titrated are not available yet. So
far there have been animal model data only for Candida, yield-
ing a predictive pharmacodynamic parameter (AUC/MIC) and
a potential target value (1), with no equivalent data for molds.
However, there is a simple HPLC/UV assay available to mon-
itor voriconazole levels. Therapeutic monitoring has been pro-
posed (4, 7) and is currently performed at our institution with
an intent to keep the trough concentration above 1 g/ml.
However, trough concentrations have never been documented
as surrogate markers of voriconazole exposure in lung trans-
plant patients.
The good correlation observed in this study between the
voriconazole trough plasma concentrations and the corre-
sponding AUC0– for both intravenous infusion (non-steady
state, R2  0.86) and oral dose (steady state, R2  0.98) (Fig.
2) indicates that trough concentration is a good measure of
voriconazole exposure in this population.
These findings are likely to be clinically relevant. Based on
Monte Carlo simulations, CF patients are very likely to expe-
rience underexposure of voriconazole and therefore need
higher doses. Mere oral administration of voriconazole is likely
to cause underexposure of voriconazole in lung transplant pa-
tients in the early posttransplant period, while intravenous
administration during the first postoperative day followed by
oral doses is likely to result in appropriate drug exposure.
However, therapeutic drug monitoring of voriconazole is still
necessary in lung transplant patients due to the large interin-
dividual variability.
In conclusion, a population pharmacokinetic model was de-
veloped for voriconazole in lung transplant patients in the early
postoperative period. Large interindividual variability in vori-
conazole pharmacokinetics was demonstrated. Bioavailability
of voriconazole is substantially lower in lung transplant pa-
tients (45.9%) than non-transplant subjects (96%) but in-
creased significantly with postoperative time, likely due to
recovery of gastrointestinal functions. Exposure and bio-
availability of voriconazole are significantly lower in CF pa-
tients, likely due to impaired absorption of voriconazole
caused by physiological changes associated with CF. We rec-
ommend intravenous infusion (6 mg/kg) during the first post-
operative day followed by oral doses (200 mg or 400 mg) as an
adequate dosing regimen in lung transplant patients. Given the
large variability in the pharmacokinetics and the good corre-
lation between AUC and trough concentrations, trough con-
centrations should be used to individualize voriconazole dose.
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